Rewrite the Future of Rare Diseases With Multiomics

Max has overall responsibility of driving CENTOGENE's Diagnostic business strategy and growth. He joins CENTOGENE from Roche Diagnostics, where he most recently served as Global Head of Medical Affairs of its Sequencing Business Unit. He came to Roche following the acquisition of Silicon Valley startup Ariosa Diagnostics Inc., where after a successful career in academic medicine, he helped build a leading global NIPT business. Prior to his medical career, Max worked as a Management Consultant for McKinsey & Company – developing and implementing strategies and solutions to overcome complex challenges in the pharmaceutical and biotechnology industry. Furthermore, he holds a medical degree from the University of Vienna and is board-certified with habilitation in Obstetrics and Gynecology and sub-specialty training in Maternal-Fetal Medicine, as well as certification in Clinical Genetics.

Prof. Peter Bauer, M.D., serves as CENTOGENE’s Chief Medical and Genomic Officer, where he combines clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing. He received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 250 publications in neurogenetics, oncogenetics, cardiogenetics, and sequencing technology.